Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia by Stride, A et al.
SHORT COMMUNICATION
Cross-sectional and longitudinal studies suggest
pharmacological treatment used in patients with glucokinase
mutations does not alter glycaemia
Amanda Stride & Beverley Shields & Olivia Gill-Carey &
Ali J. Chakera & Kevin Colclough & Sian Ellard &
Andrew T. Hattersley
Received: 7 August 2013 /Accepted: 11 September 2013 /Published online: 4 October 2013
# The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract
Aims/hypothesis Heterozygous glucokinase (GCK ) mutations
cause mild, fasting hyperglycaemia from birth. Although
patients are usually asymptomatic and have glycaemia
within target ranges, some are put on pharmacological
treatment. We aimed to investigate how many patients are
on pharmacological treatment and the impact of treatment on
glycaemic control.
Methods Treatment details were ascertained for 799 patients
with heterozygousGCK mutations. In a separate, longitudinal
study, HbA1c was obtained for 16 consecutive patients
receiving insulin (n=10) or oral hypoglycaemic agents (OHAs)
(n =6) whilst on treatment, and again having discontinued
treatment following a genetic diagnosis of GCK-MODY. For
comparison, HbA1c before and after genetic testing was
studied in a control group (n=18) not receiving pharmacological
therapy.
Results At referral for genetic testing, 168/799 (21%) of
patients were on pharmacological treatment (13.5% OHAs,
7.5% insulin). There was no difference in the HbA1c of these
patients compared with those receiving no treatment(median
[IQR]: 48 [43, 51] vs 46 [43, 50] mmol/mol, respectively;
6.5% [6.1%, 6.8%] vs 6.4% [6.1%, 6.7%]; p =0.11). Following
discontinuation of pharmacological treatment in 16 pa-
tients, HbA1c did not change. The mean change in HbA1c
was −0.68 mmol/mol (95% CI: −2.97, 1.61) (−0.06% [95%CI:
−0.27, 0.15]).
Conclusions/interpretation Prior to a genetic diagnosis, 21%
of patients were on pharmacological treatment. HbA1c was no
higher than in untreated patients and did not change when
therapy was discontinued, suggesting no impact on glycaemia.
The lack of response to pharmacological therapy is likely to
reflect the regulated hyperglycaemia seen in these patients
owing to their glucose sensing defect and is an example of
pharmacogenetics.
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Introduction
Heterozygous inactivatingGCK mutations cause mild, stable,
regulated hyperglycaemia from birth [1, 2] as a result of a
defect in glucose sensing [3]. They are a common cause of
MODY. Patients are usually asymptomatic and are typically
diagnosed incidentally, as children, in routine medicals, or
during pregnancy [1, 4].
Patients with glucokinase (GCK)-MODY rarely have HbA1c
concentrations requiring pharmacological treatment [5] but
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some patients are treated with insulin or oral hypoglycaemic
agents (OHAs) [6], especially when misdiagnosed as having
type 1 or type 2 diabetes. The birth weight of offspring is similar
for women with GCK-MODY who receive insulin during
pregnancy vs those who are not treated with insulin [7]. It
is advised that pharmacological treatment is stopped when
GCK-MODY is diagnosed but there are no formal studies
establishing the impact of treatment in these patients.
We aimed to investigate the number of patients with GCK-
MODY who are receiving pharmacological treatment and
the effect of this treatment on glycaemia using both cross-
sectional and longitudinal studies.
Methods
Subjects To investigate prevalence, in a cross-sectional study,
we studied 820 patients with GCK-MODY, from 567 families,
diagnosed at the ExeterMolecular Genetics Laboratory between
December 1993 and July 2013, for whom treatment details were
available. We excluded 21 patients with an HbA1c level above
the range seen in GCK-MODY [5] to avoid the possibility of
including patients with type 1 or type 2 diabetes.
For the longitudinal study, we studied 16 consecutive patients
with GCK-MODY, who stopped pharmacological treatment
after a genetic diagnosis was made (insulin, n =6; OHA,
n=10; follow-up details were available for all). For comparison,
we studied a control group (n =18) that was not receiving
pharmacological therapy at the time of testing. Both studies
were approved by the local research ethics committee.
Methods In the cross-sectional study we compared HbA1c, age
at diagnosis and BMI in 799 patients on no treatment, OHA or
insulin. For the longitudinal study we recorded patients’HbA1c
in the 6 months before discontinuing therapy (treatment stable
for at least 3 months) and at least 3 months after stopping
treatment. Both values were measured at the same laboratory.
Doses of oral agents were calculated as a percentage of the total
maximum dose, as previously described [8].
Statistical analysis Data are presented as medians with inter-
quartile ranges (IQRs), except change in HbA1c, which is
reported as mean and 95% CI. Differences in characteristics
between those on and off treatment were compared using the
Mann–Whitney U test. For paired analysis (i.e. changes on
and off treatment in individuals), results were compared using
the Wilcoxon test.
Results
Pharmacological treatment in 21% of patients with GCK
mutations Of 799 patients with GCK-MODY, 168 (21%)
were on pharmacological treatment at the time of genetic
testing. There were 60 patients (7.5%) on insulin and 108
(13.5%) on OHAs.
Glycaemia is similar in patients on pharmacological therapy
and in patients on no therapy There was no difference in
HbA1c in the patients on pharmacological treatment and those
not on treatment (median [IQR]: 48 [43, 51] vs 46 [43, 50]
mmol/mol, respectively; 6.5% [6.1%, 6.8%] vs 6.4% [6.1%,
6.7%]; p =0.11) (electronic supplementary material (ESM)
Table 1).
Patients on OHA treatment were older when diagnosed
with diabetes (median [IQR]: 28 [18, 42]years) than patients
on no treatment (17 [11, 30]years) or insulin (20 [8, 29]years)
(p <0.0001). BMI was higher in the OHA-treated patients
(median 25.6 kg/m2) than in patients on insulin (23.0 kg/m2)
or receiving no treatment (23.1 kg/m2) (p =0.015).
In the longitudinal therapy discontinuation study, patients
were on low doses of treatment at referral. The median dose
for the six insulin-treated patients was 0.2 U kg−1 day−1
(range: 0.1–0.8 units kg−1 day−1). In the ten patients on
OHAs the median percentage of the maximum total dose
was 33%, which equates to 660 mg of metformin or 5 mg of
glibenclamide per day.
Stopping treatment did not alter HbA1c (Fig. 1). When the
16 patients with GCK-MODY discontinued their pharmaco-
logical treatment, there was no difference between pre- and
post-treatment HbA1c levels. The mean change in HbA1c was
−0.68 (95% CI −2.97, 1.61) mmol/mol (−0.06% [95% CI
−0.27%, 0.15%]), similar to that in the group of 18 patients
who were not on treatment either prior to the genetic test or at
follow-up (see ESM Table 2).
Discussion
Our studies show that, at the time of genetic testing, 21% of
patients were on insulin or OHA treatment. Patients on
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Fig. 1 Bar chart of mean HbA1c for patients with GCK-MODY treated
with either OHAs (n =6) or insulin (n=10). Black columns represent
HbA1c during treatment and white columns represent HbA1c once treat-
ment had stopped. Error bars represent 95% CIs. To convert values for
HbA1c in mmol/mol into %, add 2.15 and divide by 10.929 or use the
conversion calculator at www.hba1c.nu/eng/
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pharmacological treatment did not have a lowerHbA1c than those
off treatment; when therapy was discontinued, HbA1c did not
rise. This suggests that the pharmacological treatment received by
patients with GCK-MODY does not alter their glycaemia.
Our study is the largest description to date of treatment in
patients with GCK-MODY, and 21% receiving pharmacological
treatment is consistent with previous series [6]. The patients on
insulin treatment were usually diagnosed as children or adoles-
cents, consistent with a misdiagnosis of type 1 diabetes. Con-
versely, the patients on OHAs were diagnosed later and had a
higher BMI, so may have been thought to have type 2 diabetes.
Patients with GCK-MODY who are on pharmacological
treatment do not have a lower HbA1c. This could either represent
a lack of action or indicate that glycaemia had been less well
controlled in these patients prior to treatment and was well
controlled as a result of the treatment. However, the lack of
change in HbA1c (95% CI: −2.97, 1.61 mmol/mol; −0.27%,
0.15%) on discontinuing treatment suggests a lack of action is
the most likely explanation. In keeping with this, in pregnancies
of womenwith GCK-MODY, the birth weight of offspring is not
altered by whether or not the mother is treated with insulin [7].
The lack of a reduction in HbA1c by hypoglycaemic therapy
is explained by patients with GCK-MODY having a glucose
level that is regulated at its raised level. This is shown in OGTTs
in which the glucose value rapidly falls towards the fasting level
[2]. Thus, if a small dose of exogenous insulin is given, there
will be a compensatory reduction in endogenous insulin secre-
tion without an alteration in glycaemia. The glucose level will
only lower when a supra-physiological insulin dose is given. In
our study, the doses of insulin and OHA were small and are
unlikely to fully suppress endogenous insulin secretion.
The lack of a glycaemic response to insulin or OHAs
is an example of pharmacogenetics, where the genetic
subtype determines treatment response. There is evidence
of pharmacogenetics for other types of monogenic diabetes.
Patients with hepatocyte nuclear factor-1α/-4α (HNF1A/
HNF4A)-MODY are sensitive to low doses of sulfonylureas
[9] and those with activating KCNJ11/ABCC8 mutations
causing neonatal diabetes are best treated with high-dose
sulfonylureas [8]. Stopping pharmacological treatment as a
consequence of identifying aGCK mutation is the first example
of a genetic subtype leading to treatment cessation.
This study was subject to limitations since it was an
observational retrospective study of a relatively small number
of patients. The ∼10% recruitment rate in the longitudinal
treatment discontinuation study reflects that when patients
are diagnosed with GCK-MODY and advised to stop treat-
ment, they are often discharged from follow-up. The clinical
characteristics of the patients included in our study are no
different from those of the patients with GCK-MODY who
were not followed-up (ESM Table 3). A prospective placebo-
controlled randomised trial would provide the ideal study
design, but would be difficult in view of the limited number
of patients. This observational study is therefore important in
the absence of such a trial.
In summary, we have shown that in patients with GCK-
MODY, treatment does not alter glycaemic control and is
unnecessary. This study provides further evidence for the role
of pharmacogenetics in diabetes care.
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